Rigorous administration of methotrexate and outcome of allogeneic blood stem cell transplantation [4]

Bone Marrow Transplantation

Volumn 39, Issue 4, 2007, Pages 243-244

  Mehta, J ^a   Singhal, S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BODY WEIGHT; CD34 SELECTION; CELL COUNT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; GRAFT RECIPIENT; HUMAN; INCIDENCE; INOCULATION; LETTER; MORTALITY; MUCOSA INFLAMMATION; NEUTROPHIL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIGENS, CD34; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; METHOTREXATE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33846976160     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705570     Document Type: Letter

References (11)

1. Mehta J, Singhal S. Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: A little methotrexate goes a long way. J Clin Oncol 2002; 20: 603-606.
2. Bensinger W. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow-transplant in the management of hematological malignancies: Indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006; 38: 539-546.
3. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet 2000; 355: 1231-1237.
4. Powles R, Mehta J, Sirohi B, Treleaven J, Kulkarni S, Singhal S et al. Bone marrow versus blood for allogeneic stem cell transplantation in patients with hematologic malignancies: Final follow-up of a double-blind, randomized prospective study. Blood (ASH Annual meeting abstracts) 2003; 102: Abstract #5584.
5. 6 CD34 + cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489-496.
6. Mehta J. Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2004; 22: 4429-4432.
7. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transprantation. Blood 2001; 98: 1695-1700.
8. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
9. Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 553-557 [Erratum in: Bone Marrow Transplant 2006; 37: 1067].
10. Ringdén O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-423.
11. Khoury HJ, Loberiza FR, Ringdén O, Barrett AJ, Bolwell BJ, Cahn JY et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712-1716.